Predictive effect of molecular and clinical characteristics for the OS and PFS efficacy of anti-PD-1/PD-L1 immunotherapy in patients with NSCLC: a meta-analysis and systematic review

Predictive effect of molecular and clinical characteristics for the OS and PFS efficacy of anti-PD-1/PD-L1 immunotherapy in patients with NSCLC: a meta-analysis and systematic review

Objective To evaluate the predictive effect of molecular and clinical characteristics for the efficacy of anti-programmed cell death 1 (PD-1)/programmed cell death ligand-1 (PD-L1) immunotherapy in patients with non-small cell lung cancer (NSCLC).Design Systematic review and meta-analysis.Setting Tw...

Full description

Saved in:

Bibliographic Details
Main Authors:	Feng Zhao, Rui An, Liqian Wang, Jikang Shan, Xianjun Wang
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2021-12-01
Series:	BMJ Open
Online Access:	https://bmjopen.bmj.com/content/11/12/e047663.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy of neoadjuvant PD-1/PD-L1 inhibitor in resectable NSCLC: a meta-analysis based on randomized controlled trials
by: Weiming Zhang, et al.
Published: (2024-12-01)

KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC
by: Jinghan Li, et al.
Published: (2024-02-01)

Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC
by: Hong Liu, et al.
Published: (2024-12-01)

Correction: KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC
by: Jinghan Li, et al.
Published: (2025-01-01)

CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
by: Francois-Xavier Danlos, et al.
Published: (2022-02-01)

PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy
by: Yimin Zheng, et al.
Published: (2023-10-01)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
by: Lin Liu, et al.
Published: (2020-10-01)

A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
by: Diana I. Albu, et al.
Published: (2024-12-01)

Enhancing immunotherapy through PD‐L1 upregulation: the promising combination of anti‐PD‐L1 plus mTOR inhibitors
by: Anna Hernández‐Prat, et al.
Published: (2025-01-01)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
by: Valerie Chew, et al.
Published: (2020-10-01)

In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma
by: Yago Pico de Coaña, et al.
Published: (2020-05-01)

Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC
by: Hui Li, et al.
Published: (2024-11-01)

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
by: Alberto Puccini, et al.
Published: (2020-05-01)

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy
by: Razelle Kurzrock, et al.
Published: (2020-05-01)

PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC
by: Chiao-En Wu, et al.
Published: (2020-01-01)

Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC
by: Florian Posch, et al.
Published: (2024-04-01)

Efficacy and Safety of Paclitaxel-Based PD-1/PD-L1 Immunotherapies for Triple-Negative Breast Cancer: A Systematic Review and Network Meta-Analysis
by: Youran Dai, et al.
Published: (2024-12-01)

PD-L1 antibodies-armed exosomal vaccine for enhanced cancer immunotherapy by simultaneously in situ activating T cells and blocking PD-1/PD-L1 axis
by: Xinyue Dai, et al.
Published: (2022-12-01)

Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
by: Francois Ghiringhelli, et al.
Published: (2021-06-01)

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC
by: Mariano Severgnini, et al.
Published: (2020-10-01)

Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care
by: Drew M Pardoll, et al.
Published: (2025-01-01)

Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab
by: Serigne Lo, et al.
Published: (2020-10-01)

From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment
by: Fang-Ju Huang, et al.
Published: (2025-12-01)

Alopecia and hair repigmentation associated with anti-programmed death-ligand 1 (PD-L1) immunotherapy
by: Jennifer Strong, BS, et al.
Published: (2025-02-01)

Enhanced therapeutic efficacy for glioblastoma immunotherapy with an oncolytic herpes simplex virus armed with anti-PD-1 antibody and IL-12
by: Lei Wang, et al.
Published: (2024-06-01)

Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy
by: Madhusudan Roy, et al.
Published: (2024-03-01)

Clinical efficacy and safety of anti PD-1/PD-L1 antibodies as monotherapy in patients with non-small-cell lung cancer
by: Marta Zayas-Soriano, et al.
Published: (2021-01-01)

Association of pre-existing conditions with major driver mutations and PD-L1 expression in NSCLC
by: Xin Zheng, et al.
Published: (2024-12-01)

Current perspectives on tertiary lymphoid structures and PD-1/PD-L1 signaling pathway in the immunotherapy of hepatocellular carcinoma
by: Hao-Dong QIAO, et al.
Published: (2023-10-01)

Mefloquine enhances the efficacy of anti-PD-1 immunotherapy via IFN-γ-STAT1-IRF1-LPCAT3-induced ferroptosis in tumors
by: Jing Chen, et al.
Published: (2024-03-01)

Oxymatrine Inhibits PD-L1 by Downregulating IFN-γ to Promote Ferroptosis and Enhance Anti-PD-L1 Efficacy in Liver Cancer
by: Nong Y, et al.
Published: (2024-12-01)

Sex-Related Differences in the Immune System Drive Differential Responses to Anti-PD-1 Immunotherapy
by: Sonja Cotra, et al.
Published: (2024-11-01)

FXR agonist GW4064 enhances anti-PD-L1 immunotherapy in colorectal cancer
by: Lu Lu, et al.
Published: (2023-12-01)

Prevotellaceae Modulates Colorectal Cancer Immune Microenvironment to Assist Anti-PD-L1 Immunotherapy
by: Song Xu, et al.
Published: (2024-12-01)

Evaluating the influence of anti-PD-1 immunotherapy combined with IMRT on thyroid dysfunction in nasopharyngeal carcinoma
by: Liqianqi Chen, et al.
Published: (2025-01-01)

Letter to the editor, “Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – Implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy.”
by: Geetha Shanmugam
Published: (2024-09-01)

Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy
by: Yogesh Godiyal, et al.
Published: (2024-12-01)

Cryoablation synergizes with anti-PD-1 immunotherapy induces an effective abscopal effect in murine model of cervical cancer
by: Xiaoming Yang, et al.
Published: (2025-01-01)

Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
by: Rangarirai Makuku, et al.
Published: (2021-01-01)

A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer
by: Shuailei Dong, et al.
Published: (2025-01-01)